Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model
Frontiers in Pharmacology · 18.03.2026 · 17
DOI: 10.3389/fphar.2026.1748522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.03.2026. Verfasst von Mohammad Ranjbari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Astaxanthin (AST) is a potent carotenoid with antioxidant properties that has garnered attention for its potential neuropharmacological effects.
Purpose
This study investigates the anxiolytic and antidepressant activities of AST in a rat model to elucidate its therapeutic potential for mood disorders. Material and Methods Fifty-four male rats were divided into nine groups receiving normal saline, astaxanthin (AST, 5, 10, and 15 mg/kg), diazepam (DZP, 0.5 mg/kg), fluoxetine (FXT, 5 mg/kg), or combinations of AST (10 mg/kg) with receptor antagonists flumazenil (FLU, GABA-A antagonist), atropine (ATR, muscarinic antagonist), and naloxone (NAL, opioid antagonist) for 14 consecutive days. At the end of the study, behavioral assessments were conducted, including the open field, light-dark box, elevated plus maze, tail suspension, and forced swimming tests. Biochemical analyses were performed to evaluate serum catalase (CAT), glutathione (GSH), nitrite, and matrix metalloproteinase-2 (MMP-2) and MMP-9 activities. Results and Discussion Astaxanthin, particularly at 10 mg/kg, significantly reduced anxiety- and depressive-like behaviors, comparable to DZP and FXT in four-week-old male Wistar rats. Pretreatment with FLU, ATR, or NAL partially reversed these effects, suggesting involvement of GABAergic, cholinergic, and opioid pathways. Furthermore, AST enhanced antioxidant defenses, evidenced by increased serum CAT and GSH levels and reduced nitrite concentrations. Gelatin zymography revealed that AST increased MMP-2 activity while slightly decreasing MMP-9 activity, a partial reversal by the aforementioned antagonists.
Conclusion
The results suggest that AST could produce anxiolytic and antidepressant effects. Such effects are likely mediated through GABAergic, cholinergic, and opioid systems, as well as antioxidant and anti-inflammatory mechanisms. Future studies should focus on well-controlled clinical trials to evaluate the preclinical results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Neurobiology Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Regenerative Medicine Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Zitieren
APA
Ranjbari, M., Fakhri, S., Abbaszadeh, F., Kiani, A., Mohammadi-Noori, E., & Echeverría, J. (2026). Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1748522
Vancouver
Ranjbari M, Fakhri S, Abbaszadeh F, Kiani A, Mohammadi-Noori E, Echeverría J. Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1748522
BibTeX
@article{Ranjbari2026,
author = {Ranjbari, Mohammad and Fakhri, Sajad and Abbaszadeh, Fatemeh and Kiani, Amir and Mohammadi-Noori, Ehsan and Echeverría, Javier},
title = {Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1748522}
}
EUVIMED